Trimetazidine: a second look. Just a placebo.
(1) Trimetazidine is licensed in France for the prevention of angina attacks and for symptomatic treatment of vertigo and tinnitus.  (2) In angina the evidence on trimetazidine is sorely lacking.  The only available comparative trial failed to show that trimetazidine monotherapy was even as good as low-dose propranolol.  For want of appropriate assessment, it is not known if trimetazidine can reinforce the activity of betablockers, the reference treatment.  (3) In symptomatic treatment of vertigo and tinnitus, the three available placebo-controlled trials show significant differences in favour of trimetazidine, but these differences are too small to be clinically relevant.  (4) Data on the adverse effect profile of trimetazidine are virtually non existent.  Gastrointestinal disorders and headache have been reported.
D000787:Angina Pectoris / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005602:France; D006801:Humans; D010919:Placebos; D011433:Propranolol / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014012:Tinnitus / Q000188:drug therapy*; D016896:Treatment Outcome; D014292:Trimetazidine / Q000009:adverse effects / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use; D014717:Vertigo / Q000188:drug therapy*
D010919:Placebos; D014665:Vasodilator Agents; D011433:Propranolol; D014292:Trimetazidine